Funding: the study was supported by the Ministry of Science and Higher Education of the Russian Federation (agreement No. 075-10-2021-113, project ID RF---193021X0001).

Acknowledgements: the authors express their gratitude to staff members of the Sirius University of Science and Technology: I.M. Terenin for in vitro transcription, O.V. Zaborova for mRNA formulation into lipid nanoparticles.

Author contribution: Shepelkova GS — planning the experiments and experimental procedure (in vivo and ex vivo), data analysis, manuscript writing; Reshetnikov VV — cloning, mRNA vaccine preparation, manuscript writing; Avdienko VG — experimental procedure (in vivo and ex vivo), data analysis; Sheverev DV — mRNA vaccine preparation, data analysis; Yeremeev VV — study design, data analysis, manuscript writing; Ivanov RA — study design, manuscript writing.

Compliance with ethical standards: the study was approved by the Ethics Committee of the Central Tuberculosis Research Institute (protocol № 3/2 dated 11 May 2023) and conducted in accordance with the Order of the Ministry of Health No. 755 and the Guidelines issued by the Office of Laboratory Animal Welfare (А5502-01).